Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

BioMarin (Phase III PARP)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Provider of drugs for the treatment of breast cancer. The company specializes in orally-available poly ADP ribose polymerase (PARP) inhibitor currently in a Phase 3 study for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Acquirer
Primary Office
  • 770 Lindaro Street
  • San Rafael, CA 94901
  • United States

BioMarin (Phase III PARP) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore BioMarin (Phase III PARP)‘s full profile, request access.

Request full access to PitchBook

BioMarin (Phase III PARP) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore BioMarin (Phase III PARP)‘s full profile, request access.

Request full access to PitchBook